TCR2 Therapeutics

Biotech

TCR2 taps ElevateBio to manufacture T-cell therapy for phase 2

TCR2's endgame was always to manufacture its T-cell therapies in-house. But, in the meantime, it's getting a little help from a Boston-area neighbor.
Amirah Al Idrus Nov 10, 2020 8:00am

TCR2's T-cell therapy curbs solid tumors in early phase 1 data

Jul 27, 2020 10:45am

TCR2 IPO hits midpoint, setting stage for trials of CAR-T rivals

Feb 15, 2019 10:15am

Immuno-oncology player TCR2 Therapeutics tees up for $80M IPO

Feb 4, 2019 10:52am

Athenex rakes in $100M, sets up Chinese TCR-focused JV

Jul 2, 2018 11:35am

Chutes & Ladders—Ex-Ariad CEO leads Roivant and Arbutus’ RNA JV

Apr 13, 2018 7:52am